Q2 EPS Estimate for Bausch Health Cos Decreased by Analyst

Bausch Health Cos Inc. (NYSE:BHC) – Equities researchers at Zacks Research cut their Q2 2027 EPS estimates for Bausch Health Cos in a research note issued to investors on Monday, July 27th. Zacks Research analyst Team now anticipates that the company will post earnings of $0.81 per share for the quarter, down from their prior forecast of $0.82. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.05 per share. Zacks Research also issued estimates for Bausch Health Cos’ Q3 2027 earnings at $1.04 EPS, Q4 2027 earnings at $0.93 EPS, FY2027 earnings at $3.59 EPS, Q1 2028 earnings at $0.57 EPS, Q2 2028 earnings at $0.81 EPS and FY2028 earnings at $3.02 EPS.

Several other equities research analysts have also weighed in on the company. Jefferies Financial Group upgraded Bausch Health Cos to a “hold” rating in a research note on Wednesday, July 22nd. Royal Bank Of Canada cut their target price on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a research report on Monday, April 27th. Finally, Weiss Ratings lowered Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 4th. Five equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $8.00.

Bausch Health Cos Stock Up 1.2%

Shares of BHC opened at $4.49 on Tuesday. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of -1.38 and a beta of 0.42. The company has a quick ratio of 0.97, a current ratio of 1.32 and a debt-to-equity ratio of 54.68. Bausch Health Cos has a 12 month low of $4.33 and a 12 month high of $8.69. The company has a 50-day moving average price of $4.98 and a two-hundred day moving average price of $5.52.

Bausch Health Cos (NYSE:BHC) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $0.78 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.03). Bausch Health Cos had a negative net margin of 11.47% and a negative return on equity of 2,922.77%. The business had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.37 billion.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Tidal Investments LLC raised its position in Bausch Health Cos by 2.6% in the 2nd quarter. Tidal Investments LLC now owns 50,131 shares of the company’s stock valued at $334,000 after purchasing an additional 1,276 shares during the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of Bausch Health Cos by 14.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 14,067 shares of the company’s stock worth $98,000 after purchasing an additional 1,812 shares during the last quarter. Pictet Asset Management Holding SA increased its stake in shares of Bausch Health Cos by 4.1% in the first quarter. Pictet Asset Management Holding SA now owns 54,169 shares of the company’s stock valued at $292,000 after buying an additional 2,114 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its stake in shares of Bausch Health Cos by 2.5% in the second quarter. CANADA LIFE ASSURANCE Co now owns 104,156 shares of the company’s stock valued at $690,000 after buying an additional 2,552 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in shares of Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock valued at $51,000 after buying an additional 3,106 shares during the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Frank D. Lee sold 24,456 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total transaction of $132,796.08. Following the completion of the sale, the director owned 49,339 shares of the company’s stock, valued at approximately $267,910.77. This trade represents a 33.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 20.67% of the company’s stock.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.